- Pomalidomide Combo Shows Deep🔍
- CARTITUDE 4🔍
- A Study of Talquetamab With Other Anticancer Therapies in ...🔍
- GSK announces positive results from DREAMM|8 phase III trial for ...🔍
- An update on targeted therapies in systemic sclerosis based on a ...🔍
- Corporate news details🔍
- A Prospective Study Of Donor Immuknow® As A Biomarker For ...🔍
- CAR T|Cell Therapy🔍
Analysis of efficacy and safety of POM as a replacement therapy for ...
Elotuzumab, pomalidomide, and dexamethasone is a very well ...
Recently, a small phase 2 study demonstrated an advantage in progression-free survival (PFS) for elo plus pomalidomide (pom)/dex compared to pom ...
the safety and efficacy of rimegepant as compared to placebo in the treatment of moderate or severe migraine. The study drug will be. Page 9 ...
Pomalidomide Combo Shows Deep, Enduring Responses in R/R ...
... safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study. ... Additionally, developers anticipate launching a new phase 3 ...
DREAMM 3 - Victorian Cancer Trials Link
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide ...
CARTITUDE 4 - Myeloma Clinical Trials
The purpose of this study is to compare the efficacy of JNJ-68284528 (ciltacabtagene autoleucel [cilta-cel]) with standard therapy.
Elotuzumab, pomalidomide, and dexamethasone is a very well ...
... analyze the efficacy and ... pom/dex compared to their most recent line of therapy. Objective responses ...
Pomalyst (Pomalidomide) for Multiple Myeloma | The IMF
Pomalyst and its metabolites are excreted by the kidneys. The influence of renal (kidney) and hepatic (liver) impairment on the safety, efficacy, and ...
A Study of Talquetamab With Other Anticancer Therapies in ...
PRNewswire 2023 - New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma ...
A positive overall survival (OS) trend favouring the Blenrep combination was also observed at the time of this analysis. The trial continues to ...
An update on targeted therapies in systemic sclerosis based on a ...
New molecular mechanisms that can be targeted with specific drugs have recently emerged for the treatment of systemic sclerosis (SSc) ...
Corporate news details - Bristol Myers Squibb - Press Releases
Pomalyst was granted accelerated approval, Breakthrough Therapy designation and Orphan Drug designation in these indications based on overall ...
A Prospective Study Of Donor Immuknow® As A Biomarker For ...
We assessed effi- cacy and safety of POM in people with corticosteroid-resistant. cGVHD. ... No ECP in the preceding 3 m or new therapy in the preceding 1 m was ...
• Efficacy after other BCMA-directed therapies. • Combination strategies. • TRIMM study: teclistamab + dara + pom. GPRC5D: G Protein-Coupled Receptor. Class C ...
In addition, OS analysis would be conducted at the second PFS interim analysis and the PFS final analysis for safety and efficacy considerations ...
Supplementary appendix - The Lancet
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double ...
This study is designed to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19 pneumonia. The primary ...
Safety, effectiveness, and pharmacokinetics of adalimumab in ...
Adverse events (AEs) were summarized for completed visits. Efficacy endpoints included American College of Rheumatology pediatric (PedACR) 30/50 ...
A study on the safety and efficacy of reveglucosidase alfa in patients ...
... replacement therapy with recombinant human ( ... POM-001/002 Investigators. Abstract. Late-onset ... This study evaluated the pharmacokinetics, safety, and ...
Clinical Trial: NCT04956042 - My Cancer Genome
This will be an open-label, Phase 1B/2A, study to characterize the efficacy, safety, pharmacokinetics, and pharmacodynamics of fosciclopirox administered ...
Recce Pharmaceuticals receives approval for Phase III DFI trial in ...
The double-blinded, placebo-controlled study to assess safety and efficacy of R327G is set to begin mid-next month. ... R327G is a topical gel ...